Table 2 |
||
|
Descriptive statistics of the 245 interventions |
||
| No. Interventions (%)Total 245 |
||
|
|
||
| Patient/disease characteristics |
||
|
|
||
| AR-DRGs |
Musculoskeletal and connective tissue |
33 (13) |
| Mental diseases and disorders |
32 (13) |
|
| Alcohol or drug use |
29 (12) |
|
| Circulatory system |
22 (9) |
|
| Endocrine nutritional and metabolic disorder/disease |
20 (8) |
|
| Infectious and parasitic diseases |
20 (8) |
|
| Other |
89 (36) |
|
| Target Age |
Children aged 0 to 14 years |
34 (14) |
| Young adults age 14 to 25 years |
5 (2) |
|
| Working age adults 25 to 65 years |
14 (6) |
|
| Elderly aged 65+ years |
20 (8) |
|
| Children and young adults aged 0 to 25 years |
2 (1) |
|
| Young adults and adults aged 14 to 65 years |
63 (26) |
|
| Adults and elderly aged 25 to 65 plus years |
92 (38) |
|
| All |
11 (5) |
|
| Mixture of the above groups |
4 (2) |
|
| Target population |
Specific |
200 (82) |
| General population |
45 (18) |
|
| Ability to reduce own risk |
To some extent |
123 (50) |
| No |
122 (50) |
|
| Condition caused by patients' own behaviour |
To some extent |
127 (52) |
| No |
118 (48) |
|
|
|
||
| Intervention details |
||
|
|
||
| Type |
Medical |
177 (72) |
| Lifestyle |
68 (28) |
|
| Objective |
Treatment |
119 (49) |
| Prevention |
78 (32) |
|
| Screening |
33 (14) |
|
| Diagnosis |
7 (3) |
|
| Combination |
8 (3) |
|
| Prevention stage |
Primary (completely avert disease) |
78 (32) |
| Secondary (slow/halt progression of disease) |
119 (49) |
|
| Tertiary (limit disability after harm) |
48 (20) |
|
| Modality |
Pharmaceutical |
52 (21) |
| Primary medical care or specialist care |
65 (27) |
|
| Community/media/education |
39 (16) |
|
| Hospital inpatient |
26 (11) |
|
| Vaccination |
17 (7) |
|
| Allied health |
29 (12) |
|
| Combination of modalities |
9 (4) |
|
| Other |
8 (3) |
|
|
|
||
| Nature of publication & study methodology |
||
|
|
||
| Year of publication |
Median (range) |
2002 (1989 to 2005) |
| Strength of evidence |
Strong-RCT/meta-analysis |
132 (54) |
| Limited |
113 (46) |
|
| Where published |
Peer reviewed journal |
185 (76) |
| Government report |
18 (7) |
|
| Other peer-reviewed report |
26 (11) |
|
| Other non peer reviewed report |
16 (7) |
|
| Publication type |
General medicine |
52 (21) |
| Specialist medicine |
85 (35) |
|
| Health economics/policy/HTA/public health |
108 (44) |
|
| Perspective |
Health system |
212 (87) |
| Societal |
33 (14) |
|
| Measure of Outcome |
Life year |
79 (32) |
| QALY |
119 (49) |
|
| DALY |
46 (19) |
|
| HYE |
1 (1) |
|
| Discount rate |
0% |
27 (13) |
| 3% |
22 (10) |
|
| 5% |
190 (78) |
|
| Missing |
12 (6) |
|
| Time horizon of the model in years |
Median |
15 |
| Interquartile range |
1 to 25 |
|
| Missing |
89 (36) |
|
| Duration of benefit in years |
Median |
4 |
| Interquartile range |
1 to 6 |
|
| Missing |
81 (33) |
|
| Downstream costs/savings |
Included |
140 (57) |
|
|
||
| Quality |
||
|
|
||
| Q-Comparator |
Appropriate |
215 (88) |
| Q-Costs |
Appropriate (marginal and clear) |
185 (76) |
| Q-Sensitivity analysis |
Performed |
239 (98) |
| Q-Overall |
Met all three requirements above |
173 (71) |
|
|
||
| Cost effectiveness |
||
|
|
||
| More effective but more costly |
214 (87) |
|
| Median |
$19,017 |
|
| Interquartile range |
$5,997 to $45,670 |
|
| Dominated |
11 (5) |
|
| Dominant |
20 (8) |
|
|
|
||
| Funding & implementation |
||
|
|
||
| Funding status |
Fully funded |
87 (35) |
| Partially funded |
75 (31) |
|
| Not funded |
83 (34) |
|
| Patients required to make contribution to costs |
Yes |
178 (73) |
|
|
||
|
Dalziel et al. Cost Effectiveness and Resource Allocation 2008 6:9 doi:10.1186/1478-7547-6-9 |
||
